Welcome to our dedicated page for Ani Pharmaceutic SEC filings (Ticker: ANIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ANI Pharmaceuticals, Inc. filings document financial results, operating updates, governance matters, and material events for its Rare Disease, Generics, and Brands businesses. Form 8-K reports furnish earnings releases, preliminary results, guidance updates, Regulation FD investor presentations, and corporate changes such as independent auditor matters.
ANI proxy filings cover shareholder voting items, board governance, executive compensation, equity awards, and related governance disclosures. The filing record also provides formal context for product and business risks tied to biopharmaceutical development, FDA-regulated generic launches, branded products, commercialization, manufacturing, and capital actions.
Lalwani Nikhil reported disposition transactions in a Form 4 filing for ANIP. The filing lists transactions totaling 21,986 shares at a weighted average price of $77.01 per share. Following the reported transactions, holdings were 358,574 shares.
ANI Pharmaceuticals SVP Ori Gutwerg reported tax-withholding share transactions tied to restricted stock vesting. On February 12, 1,775 shares of common stock were withheld at $76.7 per share, and on February 14, 1,888 shares were withheld at $77.36 per share.
These dispositions were made to cover tax obligations in connection with the vesting of 3,917 and 3,691 previously granted restricted shares. After these transactions, Gutwerg directly owned 76,094 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP Chad Gassert reported tax-withholding share transactions in company stock. On February 12, 2026, 1,608 shares of common stock were disposed of at $76.70 per share as a tax-withholding disposition tied to restricted stock vesting. On February 14, 2026, a further 1,717 shares were disposed of at $77.36 per share, also to cover tax obligations on vesting restricted stock awards.
After these transactions, Gassert directly beneficially owned 66,021 shares of ANI Pharmaceuticals common stock and indirectly beneficially owned 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power.
ANI Pharmaceuticals’ SVP and Chief HR Officer Krista Davis reported tax-related share dispositions connected to restricted stock vesting. On February 12, 2026, 1,180 shares of common stock were disposed of at $76.70 per share for tax withholding, leaving 54,367 shares held directly. On February 14, 2026, a further 1,290 shares were disposed of at $77.36 per share for tax withholding, resulting in 53,077 common shares held directly afterward. The footnotes state these were shares withheld for taxes upon vesting of 3,264 and 3,020 restricted stock shares previously granted.
ANI Pharmaceuticals senior executive Meredith W. Cook reported several stock transactions involving company common shares. On February 13, 2026, she sold 500 shares of ANI Pharmaceuticals common stock in an open-market sale at an average price of $76.8 per share under a Rule 10b5-1 trading plan adopted on September 15, 2025.
On February 12 and February 14, 2026, a total of 3,313 shares were withheld to cover tax obligations in connection with the vesting of previously granted restricted stock awards, at prices of $76.7 and $77.36 per share, respectively. After these transactions, she directly owned 67,550 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported tax-withholding share dispositions related to restricted stock vesting. On February 12, 2026, 2,829 shares of common stock were withheld at $76.7 per share to cover taxes on 6,202 vested restricted shares. On February 14, 2026, 2,448 shares were withheld at $77.36 per share to cover taxes on 5,368 vested restricted shares. After these non-market transactions, Carey directly beneficially owned 170,083 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP & CFO Stephen P. Carey reported a tax-related share disposition. On February 11, 2026, 5,503 shares of ANI Pharmaceuticals common stock were withheld at $76.25 per share to cover taxes in connection with the vesting of 16,210 performance stock units, a grant originally reported on April 6, 2023. After this non‑open‑market, tax‑withholding transaction, Carey directly beneficially owns 175,360 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals executive Meredith Cook reported a tax-related share disposition. On February 11, 2026, 3,011 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share to cover tax obligations tied to equity compensation.
The filing explains that these shares were withheld for tax purposes in connection with the vesting of 8,104 performance stock units, previously granted on April 6, 2023. After this tax-withholding transaction, Cook directly beneficially owned 71,363 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP Krista Davis reported a tax-withholding share disposition. On February 11, 2026, 3,017 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share as a tax-withholding disposition related to equity compensation.
The footnote explains that these shares were withheld for tax purposes in connection with the vesting of 8,104 performance stock units, a grant originally reported on April 6, 2023. After this transaction, Davis directly owned 55,547 shares of ANI Pharmaceuticals common stock.
ANI Pharmaceuticals SVP Chad Gassert reported a tax-related share withholding on company stock. On February 11, 2026, 4,269 shares of ANI Pharmaceuticals common stock were disposed of at $76.25 per share to cover tax obligations tied to the vesting of 11,578 performance stock units previously granted.
After this tax-withholding disposition, Gassert directly beneficially owned 69,346 shares of common stock. He also indirectly beneficially owned an additional 158,490 shares held by Chali Properties LLC, over which he holds voting and dispositive power.